Skip to main content
. 2022 Feb 23;603(7899):131–137. doi: 10.1038/s41586-022-04436-3

Fig. 3. UNC13A CE is highly expressed in tissues from patients with ALS or FTLD and correlates with known markers of TDP-43 loss of function.

Fig. 3

a, UNC13A and STMN2 CE expression from a published dataset of frontal cortex neuronal nuclei from patients with ALS or FTLD sorted according to TDP-43 expression23. b, UNC13A CE expression in bulk RNA-seq from the NYGC ALS Consortium data normalized by library size across disease and tissue samples. ALS cases are stratified by mutation status, FTLD cases are stratified by pathological subtype. c, CE expression throughout ALS-TDP and FTLD-TDP cases across tissue, number of tissue samples in brackets. d, BaseScope detection of UNC13A CE (red foci) in FTLD-TDP (9 individuals) but not control (5 individuals) or non-TDP FTLD (FTLD-TAU) (4 individuals) frontal cortex samples and quantification of background-corrected foci frequency between groups. Scale bar, 10 μm. Data are mean ± s.e.m. (b–d); Wilcoxon test.

Source data